Leadership Team

Edward Gudaitis , , , President and Chief Executive Officer

Mr. Gudaitis serves as President and Chief Executive Officer of Acerus Pharmaceuticals Corporation. Mr. Gudaitis has spent over 20 years in the pharmaceutical industry. He has extensive experience in specialty markets such as Oncology, Hepatitis, HIV, CNS and Transplantation. His functional experience spans Country leadership, Business Unit Leadership, Marketing and Sales Management, Market Access, Pricing, Health Economics and Clinical Research. Mr. Gudaitis is best known for his role as General Manager for Gilead Sciences Canada Inc. where he was responsible for leading Gilead’s Canadian affiliate from start-up in 2005 to one of the largest pharmaceutical companies in Canada in 2015 with sales of over $1 billion. He also led the launch of two significant products in the US market for Gilead as Senior Director, Marketing for Gilead’s US HIV Business. Prior to Acerus, Mr. Gudaitis served as Vice President and General Manager of Allergan Canada where he led a significant portfolio optimization process and leadership transformation. Earlier in his career he spent more than 10 years at Hoffmann-La Roche in roles of increasing responsibility. Mr. Gudaitis received his MBA from the Richard Ivey School of Business and his BSc from Brock University. He has served as Chairman of both the Ethics and Prairies Regional Committees while a board member for Innovative Medicines Canada. As well, he has served as board member for BioteCanada.

Tricia Symmes , , , Chief Operating Officer

Ms. Symmes serves as Chief Operating Officer of Acerus Pharmaceuticals Corporation, leading the development and execution of Acerus Pharma’s commercialization strategy, business development, and corporate communications. Ms. Symmes brings more than 17 years of experience in the pharmaceutical industry, most recently as the General Manager for Alcon Canada (A Novartis Company). Prior to joining Alcon, Ms. Symmes held roles of increasing responsibility within Novartis Canada including, Vice President Sales, and Vice President Specialty Medicines. Ms. Symmes holds an MBA from Charles Sturt University (Australia), an Honours BSc. in Kinesiology (Western University), and a post-graduate Management Diploma in Human Resources (Humber College).

Ken Yoon , , , Chief Financial Officer

Mr. Yoon serves as the Chief Financial Officer of Acerus Pharmaceuticals Corporation. He brings more than 20 years of experience in finance and building innovative companies. Previously, Mr. Yoon held the position of CFO and VP of Corporate Development and Corporate Secretary at Vive Crop Protection Inc. Prior to Vive, Mr. Yoon was Senior Associate, Investments – Advanced Life Sciences Fund with VenGrowth Asset Management Inc. He also held several positions at Ernst & Young, notably as a co-founder of a multi-disciplinary business advisory providing consulting services to growth companies in life sciences. Mr. Yoon is a Chartered Professional Accountant (CPA, CA) and holds an M.B.A. from the University of Toronto, a Law Degree from Queen’s University and a B.Sc. from the University of Western Ontario. He is also the treasurer and a Director at the Royal Canadian Institute and is a recipient of the Queen Elizabeth II Diamond Jubilee Medal for contribution to the advancement of sciences.

Dr. Nathan Bryson , , , Chief Scientific Officer

Dr. Bryson joined Acerus from Cynapsus Therapeutics where he served as Chief Scientific Officer. He brings more than 20 years of experience in pharmaceutical development, having held scientific and executive management level positions at several pharmaceutical companies including Flamel Technologies SA, Bionisis SA, and Matregen Corporation. Dr. Bryson holds a BSc in Chemistry from Auburn University and a PhD in Radiopharmaceutical Chemistry from the Massachusetts Institute of Technology (“MIT”). He performed post-doctoral research under two well-esteemed chemists, the late Dr. J. Osborn at the University Louis Pasteur (Strasbourg, France) and Dr. D. Seyferth at MIT.

Philippe Savard , , , Vice President, General Counsel and Corporate Secretary

Mr. Savard serves as Vice President, General Counsel and Corporate Secretary with responsibility for protecting the legal interests of Acerus and managing its legal affairs. Prior to joining Acerus, Mr. Savard was Director & Counsel at DRI Capital Inc., a firm which manages private equity funds that purchase royalties owed on the sales of pharmaceutical products. Prior to his time at DRI Capital, Mr. Savard worked as an associate at the law firm of Paul, Weiss, Rifkind, Wharton & Garrison LLP in Toronto, with a practice focused on transactional corporate securities, and as an associate at the law firm of Ropes & Gray LLP in New York, with a practice focused on corporate securities, mergers and acquisition and private equity. Mr. Savard holds a B. Sc. and a M. Sc. in Microbiology and Immunology from McGill University, a J.D. from the University of Toronto and a M.B.A. from the Rotman School of Management (University of Toronto).